Dr. Wang on Challenges Treating Patients With Relapsed/Refractory MCL

Michael Wang, MD
Published: Wednesday, Jun 12, 2019



Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses challenges in treating patients with relapsed/refractory mantle cell lymphoma (MCL).

Relapsed/refractory MCL is more common among patients with high-risk features such as high Ki-67, a blastoid or pleomorphic karyotype, p53 mutation, or a complex chromosomal karyotype, says Wang. Curative therapies do not exist for these patients; therefore, the best chance of combatting the disease lies in cellular therapies.

Many trials are ongoing in this space. For example, the phase I TRANSCEND NHL 001 trial (NCT02631044) is examining the anti–CD19 CAR T-cell therapy lisocabtagene maraleucel (liso-cel; JCAR017) in patients with relapsed/refractory disease. Preliminary results presented by Wang at the 2019 ASCO Annual Meeting indicated an overall response rate of 78% and tolerable toxicity with the therapy. Additionally, there is the phase II ZUMA-2 trial, which is testing the activity of axicabtagene ciloleucel (axi-cel; Yescarta), results for which are likely to be presented at the 2019 ASH Annual Meeting.
SELECTED
LANGUAGE


Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses challenges in treating patients with relapsed/refractory mantle cell lymphoma (MCL).

Relapsed/refractory MCL is more common among patients with high-risk features such as high Ki-67, a blastoid or pleomorphic karyotype, p53 mutation, or a complex chromosomal karyotype, says Wang. Curative therapies do not exist for these patients; therefore, the best chance of combatting the disease lies in cellular therapies.

Many trials are ongoing in this space. For example, the phase I TRANSCEND NHL 001 trial (NCT02631044) is examining the anti–CD19 CAR T-cell therapy lisocabtagene maraleucel (liso-cel; JCAR017) in patients with relapsed/refractory disease. Preliminary results presented by Wang at the 2019 ASCO Annual Meeting indicated an overall response rate of 78% and tolerable toxicity with the therapy. Additionally, there is the phase II ZUMA-2 trial, which is testing the activity of axicabtagene ciloleucel (axi-cel; Yescarta), results for which are likely to be presented at the 2019 ASH Annual Meeting.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x